eMedicine Specialties > Pulmonology > Infectious Lung Diseases

Histoplasmosis

Author: Jazeela Fayyaz, DO, Senior Fellow, Department of Pulmonology, Lenox Hill Hospital
Coauthor(s): Klaus-Dieter Lessnau, MD, FCCP, Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital
Contributor Information and Disclosures

Updated: Aug 14, 2009

Introduction

Background

Histoplasma capsulatum is a dimorphic fungus that remains in a mycelial form at ambient temperatures and grows as yeast at body temperature in mammals. Infection causes histoplasmosis. Although the fungus that causes histoplasmosis can be found in temperate climates throughout the world, it is endemic to the Ohio, Missouri, and Mississippi River valleys in the United States. Internationally, the fungus is predominantly found in river valleys in North and Central America, eastern and southern Europe, and parts of Africa, eastern Asia, and Australia. 

The soil in areas endemic for histoplasmosis provides an acidic damp environment with high organic content that is good for mycelial growth. Highly infectious soil is found near areas inhabited by bats and birds. Birds cannot be infected by the fungus and do not transmit the disease; however, bird excretions contaminate the soil, thereby enriching the growth medium for the mycelium. In contrast, bats can become infected, and they transmit histoplasmosis through droppings. Contaminated soil can be potentially infectious for years. Outbreaks of histoplasmosis have been associated with construction and renovation activities that disrupt contaminated soil. In addition, travelers to endemic areas are at risk for histoplasmosis because airborne spores can travel hundreds of feet.1

Most individuals with histoplasmosis are asymptomatic. Those who develop clinical manifestations are usually immunocompromised or are exposed to a high quantity of inoculum. Histoplasma species may remain latent in healed granulomas and recur, resulting in cell-mediated immunity impairment.

Pathophysiology

H capsulatum in the saprobic state grows in the mycelial form. Macroconidia and microconidia are produced on the hyphae of mycelium and are converted to the yeast form under temperature-controlled regulation.  The aerosolization of conidia and mycelial fragments from contaminated soil results in alveolar deposition via inhalation.

The host defense includes the fungistatic properties of neutrophils and macrophages. T lymphocytes are crucial in limiting the extent of infection. Susceptibility to dissemination is increased markedly with impaired cellular host defenses.

Conversion from the mycelial to the pathogenic yeast form occurs intracellularly. After phagocytosis by macrophages, the yeast replicates in approximately 15-18 hours. Despite fusion with lysosomes, multiplication continues within the phagosomes. Proposed theories suggest that the yeasts may produce proteins that inhibit the activity of lysosomal proteases.

As the host immunity response develops, yeast growth ceases within 1-2 weeks after exposure. Cytokines systemically activate the fungistatic activity of macrophages against intracellular yeasts. With further maturation of the cell-mediated response, delayed-type hypersensitivity to histoplasmal antigens occurs (3-6 wk after exposure). Approximately 85-90% of individuals who are immunocompetent produce a positive response to skin antigen test for Histoplasma species.2 Over weeks to months, the inflammatory response produces calcified fibrinous granulomas with areas of caseous necrosis.

Clinical manifestations of histoplasmosis appear with continued exposure to large inocula. The initial pulmonary infection may disseminate systemically, with hematogenous spread, and produce extrapulmonary manifestations. Hematogenous spread to regional lymph nodes may occur through the lymphatics or the liver and spleen. Progressive disseminated histoplasmosis is rare in adult hosts who are immunocompetent. Systemic spread usually occurs in patients with impaired cellular immunity and typically involves the CNS, liver, spleen, and rheumatologic, ocular, and hematologic systems.

Frequency

United States

Histoplasmosis is the most common endemic fungal infection seen in humans. The central river valleys in the midwestern and south central United States are endemic for histoplasmosis. Approximately 250,000 individuals are infected annually. Clinical manifestations of histoplasmosis occur in less than 5% of the population. Most infections are sporadic, although large outbreaks of histoplasmosis may occur.

Population studies have demonstrated that greater than 80% of young adults from endemic areas (Ohio Valley, Mississippi Valley) have been previously infected with H capsulatum.3

International

The fungus is predominantly found in river valleys between latitudes 45° north and 30° south in South and Central America.4

Mortality/Morbidity

Morbidity and mortality are related to the duration and extent of systemic infection.

  • Approximately 90% of patients with acute pulmonary histoplasmosis are asymptomatic. Acute pericarditis can occur in as many as 5% of patients who are symptomatic.1 The pericardial fluid is generally exudative.4 Pleural effusions develop in 40-60% of patients with pericarditis.
  • Chronic pulmonary histoplasmosis occurs in patients with underlying lung disease. Patients develop cavities that may enlarge and result in necrosis. Untreated histoplasmosis may lead to progressive pulmonary fibrosis that results in respiratory and cardiac failure and recurrent infections.
  • Progressive disseminated histoplasmosis occurs in 1 case per 2000 cases in adults who are immunocompetent. Progressive disseminated histoplasmosis occurs in 4-27% of infected children, older individuals, persons who are immunosuppressed. In the subacute form, death occurs within 2-24 months in untreated cases. The acute form, if untreated, results in death within weeks.3

Sex

The rates of positive results on skin testing for sensitivity to antigens of H capsulatum are similar in males and females. Rheumatologic manifestations tend to occur predominantly in females.6

Age

Although histoplasmosis can affect individuals of any age, those in extreme age ranges are more prone to developing infection as a result of immature or deteriorated immune defenses.

Clinical

History

A thorough social and occupational history is essential in the initial evaluation of histoplasmosis. Travel or residence in an endemic area or activities involving bats or birds, whether recent or remote, should aid in the differential. Determine if the patient has a drug history or comorbid condition that is contributing to an immunocompromised state. The diagnosis of histoplasmosis should be considered in anyone with an acute febrile respiratory illness who has traveled to an area where histoplasmosis is endemic.1

  • Acute pulmonary histoplasmosis
    • Approximately 90% of patients are asymptomatic.
    • If symptoms develop, onset occurs 3-14 days after exposure.6
    • Fever, headache, malaise, myalgia, abdominal pain, and chills are common symptoms; usually, histoplasmosis is self-limited.
    • Individuals exposed to a large inoculum may develop severe dyspnea resulting from diffuse pulmonary involvement.
    • Joint pain and skin lesions occur in 5-6% of patients, mostly in females.3
    • Enlarged hilar and mediastinal lymph nodes are present in 5-10% of patients.
    • Cough, hemoptysis, dyspnea, and/or chest pain may be present and are related to the degree of compression on the pulmonary airway and circulation. Paratracheal involvement may cause cough or dyspnea because of compression on the trachea or bronchi. Rarely, compression of the esophagus occurs, which causes dysphagia.
  • Chronic pulmonary histoplasmosis
    • This form occurs mostly in older patients with underlying pulmonary disease and is associated with cough, weight loss, fevers, and malaise. 
    • Generally, infection involves the apical segments and occurs near emphysematous bullae. Pleural thickening is often seen.3
    • If cavitations are present, hemoptysis, sputum production, and increasing dyspnea are common symptoms.
  • Progressive disseminated histoplasmosis
    • This form occurs mostly in hosts who are immunocompromised.
      • Major risk factors include exposure to the fungus as an infant, AIDS with CD4 count of less than 150 cells/µL, use of corticosteroids, hematologic malignancy, and solid organ transplantation.
      • Patients requiring tumor necrosis factor antagonists (eg, etanercept, infliximab) are also an increased risk for disseminated histoplasmosis.4  
    • After initial exposure, H capsulatum may remain dormant, and reactivation may occur years after initial exposure. The organism may even be transmitted with donated organs.4
    • Symptoms vary depending on duration of illness. 
      • The acute form may produce fever, worsening cough, weight loss, malaise, and dyspnea. Approximately 5-20% of patients have CNS involvement.
      • The subacute form is associated with a wide spectrum of symptoms that may occur as a result of dissemination and subacute expression in the affected organs. Aside from constitutional symptoms, gastrointestinal involvement may produce diarrhea and abdominal pain. Cardiac involvement resulting in valvular disease, cardiac insufficiency, or vegetations may produce dyspnea, peripheral edema, angina, and fever. CNS involvement may produce headache, visual and gait disturbances, confusion, seizures, altered consciousness, and neck stiffness or pain.
      • The chronic form is associated with constitutional symptoms. Mucous membrane lesions are common in disseminated histoplasmosis.3
  • Presumed ocular histoplasmosis syndrome
    • Approximately 1-10% of individuals living in endemic areas have ocular involvement that is usually asymptomatic.6
    • Macula involvement may result in blindness.
  • Mediastinitis
    • Granulomatous mediastinitis may result from enlargement of multiple nodes that undergo necrosis.
    • Fibrosing mediastinitis is an uncommon complication associated with excessive fibrosis that invades the structures of the mediastinum. Most patients are young adults, and women are more commonly affected than men.3

Physical

Findings on a physical examination are related to the extent and duration of infection.

  • Acute pulmonary histoplasmosis
    • Findings are usually minimal.
    • Approximately 5-6% of patients develop rheumatologic manifestations of erythema multiforme, arthritis, and erythema nodosum.3
    • Auscultation may rarely reveal rales or wheezes. In cases with high inoculum, individuals may develop severe hypoxemia associated with rales that may mimic acute respiratory distress syndrome. Approximately 10% of patients have asymptomatic pleural effusions.6
    • In 5% of patients, pericarditis may be present and can be associated with rubs.7
    • Hepatosplenomegaly may occasionally be present.
  • Chronic pulmonary histoplasmosis: This form may manifest during pulmonary auscultation as nonspecific rales, wheezes, or findings consistent with the extent of underlying pneumonitis, consolidation, or cavitation.
  • Chronic progressive disseminated histoplasmosis: This condition may produce oropharyngeal ulcers involving the buccal mucosa, tongue, gingiva, and larynx. Lesions do not suggest dissemination. Rare cases of isolated lesions have been seen in individuals who are immunocompetent.
  • Subacute progressive disseminated histoplasmosis
    • Gastrointestinal dissemination may result in abdominal mass or intestinal ulcers and lesions. Surgical abdomen may result from intussusception, perforation, or obstruction.
    • CNS dissemination may produce findings associated with possible mass lesions or meningismus, including cranial nerve deficits, muscle weakness, ataxia, altered consciousness, or focal deficits.
    • Cardiac dissemination may result in signs and complications of endocarditis, including murmurs, peripheral edema, pulmonary rales or wheezes, petechia, or skin lesions.
  • Acute progressive disseminated histoplasmosis
    • CNS manifestations that include a mass lesion, encephalopathy, and meningitis (as observed in the subacute form) occur in 5-20% of patients.
    • Hepatosplenomegaly and lymphadenopathy may be present. Superior vena cava (SVC) syndrome may be present with lymphadenopathy severe enough to cause obstruction. The resulting increased venous pressure may manifest as dilatation of collaterals in the neck and thorax; edema of the face, neck, and upper torso; and conjunctiva.
    • Cutaneous lesions are present in 10% of patients. Erythematous maculopapular lesions, ulcerations, purpura, and/or manifestations of endocarditis may be present. Oropharyngeal lesions may also be present.4
  • Presumed ocular histoplasmosis syndrome
    • Atrophic scars containing foci of lymphocytic cell infiltration termed histo spots may be present and are located posterior to the equator of the eye.
    • If the scars are located on the macula, retinal hemorrhage, detachment, or edema may be present.

Causes

The risk of infection is mostly related to environmental exposure and underlying immune status.

  • Endemic areas: Living in endemic areas with contaminated soil increases the risk of exposure.
  • Inoculum size
    • Individuals who are immunocompetent and exposed to a low inoculum of histoplasmosis are usually asymptomatic.
    • Inhalation of a large inoculum can cause diffuse pulmonary symptoms that may have a protracted course.
  • Immune status and comorbid factors
    • Reactivation, reinfection, or complications of infection usually occur in individuals who are immunocompromised or immunosuppressed.
    • Chronic pulmonary histoplasmosis is more prevalent in patients with underlying emphysema.

More on Histoplasmosis

Overview: Histoplasmosis
Differential Diagnoses & Workup: Histoplasmosis
Treatment & Medication: Histoplasmosis
Follow-up: Histoplasmosis
References
Further Reading

References

  1. Outbreak of histoplasmosis among travelers returning from El Salvador--Pennsylvania and Virginia, 2008. MMWR Morb Mortal Wkly Rep. Dec 19 2008;57(50):1349-53. [Medline].

  2. Lowell JR. Diagnosis of histoplasmosis. Ann Intern Med. Feb 1983;98(2):260. [Medline].

  3. Kauffman CA. Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev. Jan 2007;20(1):115-32. [Medline].

  4. Kauffman CA. Histoplasmosis. Clin Chest Med. Jun 2009;30(2):217-25, v. [Medline].

  5. Hage CA, Wheat LJ, Loyd J, Allen SD, Blue D, Knox KS. Pulmonary histoplasmosis. Semin Respir Crit Care Med. Apr 2008;29(2):151-65. [Medline].

  6. Picardi JL, Kauffman CA, Schwarz J, Holmes JC, Phair JP, Fowler NO. Pericarditis caused by Histoplasma capsulatum. Am J Cardiol. Jan 1976;37(1):82-8. [Medline].

  7. Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther. Nov 2006;6(11):1207-21. [Medline].

  8. Corcoran GR, Al-Abdely H, Flanders CD, Geimer J, Patterson TF. Markedly elevated serum lactate dehydrogenase levels are a clue to the diagnosis of disseminated histoplasmosis in patients with AIDS. Clin Infect Dis. May 1997;24(5):942-4. [Medline].

  9. Wheat LJ, Kohler RB, Tewari RP. Diagnosis of disseminated histoplasmosis by detection of Histoplasma capsulatum antigen in serum and urine specimens. N Engl J Med. Jan 9 1986;314(2):83-8. [Medline].

  10. Davies SF, Rohrbach MS, Thelen V, et al. Elevated serum angiotensin-converting enzyme (SACE) activity in acute pulmonary histoplasmosis. Chest. Mar 1984;85(3):307-10. [Medline].

  11. [Guideline] Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45:807-825.

  12. Bennish M, Radkowski MA, Ripon JW. Cavitation in acute histoplasmosis. Chest. Oct 1983;84(4):496-7. [Medline].

  13. Wheat J, Hafner R, Wulfsohn M, et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. Apr 15 1993;118(8):610-6. [Medline].

  14. Davies SF, Khan M, Sarosi GA. Disseminated histoplasmosis in immunologically suppressed patients. Occurrence in a nonendemic area. Am J Med. Jan 1978;64(1):94-100. [Medline].

  15. Goldman M, Johnson PC, Sarosi GA. Fungal pneumonias. The endemic mycoses. Clin Chest Med. Sep 1999;20(3):507-19. [Medline].

  16. Goodwin RA, Alcorn GL. Histoplasmosis with symptomatic lymphadenopathy. Chest. Feb 1980;77(2):213-5. [Medline].

  17. Goodwin RA, Loyd JE, Des Prez RM. Histoplasmosis in normal hosts. Medicine (Baltimore). Jul 1981;60(4):231-66. [Medline].

  18. Newman SL, Gootee L, Bucher C, Bullock WE. Inhibition of intracellular growth of Histoplasma capsulatum yeast cells by cytokine-activated human monocytes and macrophages. Infect Immun. Feb 1991;59(2):737-41. [Medline].

  19. Paya CV, Roberts GD, Cockerill FR 3rd. Transient fungemia in acute pulmonary histoplasmosis: detection by new blood-culturing techniques. J Infect Dis. Aug 1987;156(2):313-5. [Medline].

  20. Salzman SH, Schindel ML, Aranda CP, Smith RL, Lewis ML. The role of bronchoscopy in the diagnosis of pulmonary tuberculosis in patients at risk for HIV infection. Chest. Jul 1992;102(1):143-6. [Medline].

  21. Salzman SH, Smith RL, Aranda CP. Histoplasmosis in patients at risk for the acquired immunodeficiency syndrome in a nonendemic setting. Chest. May 1988;93(5):916-21. [Medline].

  22. Wheat J. Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature. Medicine (Baltimore). Sep 1997;76(5):339-54. [Medline].

  23. Wheat LJ. Systemic fungal infections: diagnosis and treatment. I. Histoplasmosis. Infect Dis Clin North Am. Dec 1988;2(4):841-59. [Medline].

  24. Wheat LJ, Batteiger BE, Sathapatayavongs B. Histoplasma capsulatum infections of the central nervous system. A clinical review. Medicine (Baltimore). Jul 1990;69(4):244-60. [Medline].

  25. Wheat LJ, Conces D, Allen SD, Blue-Hnidy D, Loyd J. Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Semin Respir Crit Care Med. Apr 2004;25(2):129-44. [Medline].

  26. Wheat LJ, Wass J, Norton J, Kohler RB, French ML. Cavitary histoplasmosis occurring during two large urban outbreaks. Analysis of clinical, epidemiologic, roentgenographic, and laboratory features. Medicine (Baltimore). Jul 1984;63(4):201-9. [Medline].

Further Reading

Murray & Nadel's Textbook of Respiratory Medicine. 4th ed. 2005. WB Saunders; Philadelphia, Pa. Chapter 34.

Keywords

histoplasmosis, Histoplasma capsulatum, H capsulatum, Histoplasma species, dimorphic fungus, yeast, bat droppings, bird droppings, acute pulmonary histoplasmosis, pleural effusion, pericarditis, chronic pulmonary histoplasmosis, pulmonary fibrosis, mycelium, macroconidia, microconidia, progressive disseminated histoplasmosis, ocular histoplasmosis syndrome, chronic progressive disseminated histoplasmosis, subacute progressive disseminated histoplasmosis, acute progressive disseminated histoplasmosis

Contributor Information and Disclosures

Author

Jazeela Fayyaz, DO, Senior Fellow, Department of Pulmonology, Lenox Hill Hospital
Jazeela Fayyaz, DO is a member of the following medical societies: American College of Physicians and American Thoracic Society
Disclosure: Nothing to disclose.

Coauthor(s)

Klaus-Dieter Lessnau, MD, FCCP, Clinical Associate Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory; Director of Research in Pulmonary Medicine, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital
Klaus-Dieter Lessnau, MD, FCCP is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, American Medical Association, American Society for Artificial Internal Organs, American Thoracic Society, Physicians for Social Responsibility, and Society of Critical Care Medicine
Disclosure: sepracor Ownership interest None

Medical Editor

Michael Peterson, MD, Chief of Medicine, Vice-Chair of Medicine, University of California at San Francisco; Endowed Professor of Medicine, University of California at San Francisco-Fresno
Michael Peterson, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and American Thoracic Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Om Prakash Sharma, MD, FRCP, FCCP, DTM&H, Professor, Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Southern California Keck School of Medicine
Om Prakash Sharma, MD, FRCP, FCCP, DTM&H is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Chest Physicians, American College of Physicians, American Federation for Medical Research, American Osler Society, American Thoracic Society, New York Academy of Medicine, and Royal Society of Medicine
Disclosure: Keck School of Medicine, USC None None

CME Editor

Timothy D Rice, MD, Associate Professor, Departments of Internal Medicine and Pediatrics and Adolescent Medicine, Saint Louis University School of Medicine
Timothy D Rice, MD is a member of the following medical societies: American Academy of Pediatrics and American College of Physicians
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.